US · OSUR · MEDICAL - INSTRUMENTS & SUPPLIES
OraSure Technologies, Inc. (OSUR) intrinsic value and stock valuation
$3.46as of 2026-11-21 · Mkt cap 278.84M
Data updated · price as of 2026-11-21
- P/E
- Pro
- P/B
- Pro
- P/S
- Pro
Price history
Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.
OraSure Technologies, Inc. DCF and intrinsic value
InvestorsCraft values OSUR with the Chepakovich two-stage DCF model — currently rated strongly undervalued. How the model works · Run your own DCF prefilled from OSUR’s statements →
OraSure Technologies, Inc. Graham Number
The Graham Number is not defined for negative earnings or book value. Guide · Calculator →
How the business is doing
Fiscal 2011–2025, USD
Is it expensive?
Each multiple against its own 15-year range, or against peers where no history is available
Peers
Same-industry companies, ranked by market cap
Peer comparison
The peer comparison table is shown only to users with a Pro subscription.
Financials
Statements by fiscal year
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $115M | $185.8M | $405.5M | $387.5M | $233.7M |
| Operating income | -$-68.12M | -$-20.6M | $54.1M | -$-5.24M | -$-11.65M |
| Net income | -$-68.73M | -$-19.5M | $53.7M | -$-17.13M | -$-23M |
| EPSd | -$-935.36K | -$-261.99K | $721.3K | -$-236.28K | -$-319.53K |
| Operating cash flow | -$-50K | $27.4M | $141.6M | -$-47.2M | -$-35.38M |
| Capital expenditure | -$0.00 | -$-3.8M | -$-10.3M | -$-63.91M | -$-48.12M |
| Free cash flow | -$-50K | $23.6M | $131.3M | -$-111.11M | -$-83.5M |
| Total assets | $403.2M | $479.7M | $482.9M | $444.2M | $461M |
| Total debt | $13.2M | $14.6M | $13.5M | $12.6M | $12.3M |
| Net debt | -$-186.08M | -$-253.16M | -$-276.9M | -$-71.43M | -$-104.49M |
| Total equity | $340.8M | $410.3M | $430.7M | $364.4M | $380.5M |
| Cash and short-term investments | $199.3M | $267.8M | $290.4M | $110.9M | $153M |
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $115M | $185.8M | $405.5M | $387.5M | $233.7M |
| Cost of revenue | $66.8M | $109.6M | $226.1M | $239M | $116.1M |
| Gross profit | $48.2M | $76.2M | $179.4M | $148.4M | $117.6M |
| Research and development expenses | $42.5M | $24.4M | $33.2M | $36.2M | $34.2M |
| Selling, general and administrative expenses | $73.8M | $72.4M | $92.2M | $117.4M | $95.1M |
| Other expenses | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating expenses | $116.3M | $96.8M | $125.3M | $153.7M | $129.3M |
| Cost and expenses | $183.2M | $206.4M | $351.4M | $392.7M | $245.3M |
| Interest income | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Interest expense | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Depreciation and amortization | $9.97M | $10.9M | $19.9M | $14M | $11.7M |
| Ebitda | -$-56.96M | -$-6.83M | $76.2M | -$-1.68M | $2.37M |
| Operating income | -$-68.12M | -$-20.6M | $54.1M | -$-5.24M | -$-11.65M |
| Total other income/expenses, net | $1.19M | $2.9M | $2.18M | -$-10.43M | $2.36M |
| Income before tax | -$-66.93M | -$-17.7M | $56.3M | -$-15.68M | -$-9.29M |
| Income tax expense | $1.8M | $1.8M | $2.6M | $1.46M | $13.7M |
| Net income | -$-68.73M | -$-19.5M | $53.7M | -$-17.13M | -$-23M |
| Weighted average shares outstanding | $73.5M | $74.4M | $73.4M | $72.5M | $72M |
| Weighted average diluted shares outstanding | $73.5M | $74.4M | $74.4M | $72.5M | $72M |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash and short-term investments | $199.3M | $267.8M | $290.4M | $110.9M | $153M |
| Net receivables | $22.2M | $23.8M | $40.2M | $70.8M | $45.3M |
| Inventory | $31.1M | $34.2M | $47.6M | $95.7M | $53.1M |
| Total current assets | $261.9M | $333.2M | $386.5M | $325.2M | $299.3M |
| Property, plant and equipment, net | $51.3M | $58.7M | $58.3M | $71.1M | $85M |
| Goodwill and intangible assets | $62.4M | $57.8M | $36.9M | $46.8M | $54.6M |
| Long-term investments | $26M | $28.3M | $0.00 | $0.00 | $17M |
| Total non-current assets | $141.3M | $146.4M | $96.4M | $119M | $161.7M |
| Total assets | $403.2M | $479.7M | $482.9M | $444.2M | $461M |
| Accounts payable | $6.52M | $8.17M | $13.2M | $38M | $28M |
| Short-term debt | $2.23M | $2.17M | $2.12M | $2.94M | $3.12M |
| Deferred revenue | $1.52M | $2.96M | $1.56M | $2.27M | $2.94M |
| Total current liabilities | $39.8M | $33.5M | $39.5M | $69.1M | $68.1M |
| Long-term debt | $11M | $12.4M | $11.4M | $9.6M | $9.15M |
| Deferred revenue, non-current | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total non-current liabilities | $22.6M | $35.8M | $12.6M | $10.7M | $12.4M |
| Capital lease obligations | $13.2M | $14.6M | $13.5M | $12.6M | $12.3M |
| Total liabilities | $62.3M | $69.3M | $52.2M | $79.8M | $80.5M |
| Common stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Retained earnings | -$-172.16M | -$-103.43M | -$-83.93M | -$-137.59M | -$-120.45M |
| Accumulated other comprehensive income (loss) | -$-18.4M | -$-24.36M | -$-14.94M | -$-18.43M | -$-10.08M |
| Total equity | $340.8M | $410.3M | $430.7M | $364.4M | $380.5M |
| Total investments | $26M | $28.3M | $0.00 | $26.9M | $53.3M |
| Total debt | $13.2M | $14.6M | $13.5M | $12.6M | $12.3M |
| Net debt | -$-186.08M | -$-253.16M | -$-276.9M | -$-71.43M | -$-104.49M |
Cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net income | -$-70K | -$-19.5M | $53.7M | -$-17.93M | -$-23M |
| Depreciation and amortization | $10K | $10.9M | $20.9M | $15.5M | $12.5M |
| Stock-based compensation | $10K | $11.9M | $10.7M | $11.6M | $7.81M |
| Change in working capital | -$-6.8M | $18.8M | $45.8M | -$-70.56M | -$-38.44M |
| Accounts receivable | $1.95M | $15.9M | $31.1M | -$-25.16M | -$-6.45M |
| Inventory | $3.56M | $13.1M | $48.2M | -$-43.05M | -$-27.94M |
| Accounts payable | -$-1.72M | -$-7.58M | -$-26.98M | $3.96M | $3.23M |
| Net cash provided by operating activities | -$-50K | $27.4M | $141.6M | -$-47.2M | -$-35.38M |
| Investments in property, plant and equipment | -$0.00 | -$-3.8M | -$-10.3M | -$-63.91M | -$-48.12M |
| Acquisitions, net | -$0.00 | -$-5.04M | $0.00 | $120K | $0.00 |
| Net cash used for investing activities | -$-10K | -$-39.03M | $66.2M | $21.1M | -$-5.5M |
| Common stock issued | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Common stock repurchased | -$-15.04M | -$-3.55M | -$-1.9M | -$-2.25M | -$-2.11M |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash used for financing activities | -$-20K | -$-4.18M | -$-3.02M | -$-3.83M | -$-2.82M |
| Net change in cash | -$-70K | -$-22.64M | $206.4M | -$-32.78M | -$-44.04M |
| Cash at end of period | $200K | $267.8M | $290.4M | $84M | $116.8M |
| Operating cash flow | -$-50K | $27.4M | $141.6M | -$-47.2M | -$-35.38M |
| Capital expenditure | -$0.00 | -$-3.8M | -$-10.3M | -$-63.91M | -$-48.12M |
| Free cash flow | -$-50K | $23.6M | $131.3M | -$-111.11M | -$-83.5M |
Line items
Line items
Line items
About OraSure Technologies, Inc.
OraSure Technologies, Inc. and its affiliates are a global leader in the development, production, and commercialization of advanced oral fluid diagnostic solutions and specialized specimen collection tools, serving markets across the United States, Europe, and other international regions. The company operates through two primary divisions: Diagnostics and Molecular Solutions. Its diverse Diagnostics portfolio features a range of crucial offerings, such as the InteliSwab rapid tests for COVID-19 (including professional and prescription versions). It also provides several OraQuick rapid tests, encompassing solutions for HIV (Rapid, In-Home, and Self-Test versions), Hepatitis C (HCV rapid antibody), and Ebola (rapid antigen). Further diagnostic tools include the OraSure oral fluid collection device, utilized for HIV-1 antibody screening and confirmation; the Intercept drug testing systems; various immunoassay tests and reagents; and the Q.E.D. saliva alcohol test. Within its Molecular Solutions segment, OraSure offers an array of genomic products, notably under the Oragene and ORAcollect brand names, alongside specialized microbiome collection solutions and comprehensive GenoFIND genomics laboratory services. The company also supplies collection devices like ORAcollect, RNA, OMNIgene, and RAL, specifically designed for COVID-19 molecular testing. Another key offering is the Colli-Pee device, engineered for the precise volumetric collection of first-void urine. Furthermore, OraSure produces and distributes advanced kits for the collection, stabilization, transportation, and storage of genetic material samples, critical for molecular testing in diverse fields such as academic research, commercial applications (including ancestry, disease risk management, lifestyle analysis), and animal testing. Complementing these, it also provides various other diagnostic tools, including immunoassays and in vitro diagnostic tests. OraSure's sophisticated products and services are distributed to a wide array of clients, including clinical laboratories, hospitals, clinics, various community and public health organizations, wholesale distributors, governmental bodies, medical practices, and a broad spectrum of commercial and industrial entities. Established in 2000, OraSure Technologies, Inc. maintains its corporate headquarters in Bethlehem, Pennsylvania.
- CEO
- Carrie Eglinton Manner
- Employees
- 501
- Beta
- 1.00
Included in
Explore
Frequently asked questions
What is the intrinsic value of OraSure Technologies, Inc. (OSUR)?
OraSure Technologies, Inc. (OSUR) is currently strongly undervalued based on the InvestorsCraft IC model — IC value is more than 50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.
Is OSUR undervalued?
OSUR trades at a price of $3.46 (Nov 21, 2026): strongly undervalued — IC value is more than 50% above the price.
How is the intrinsic value calculated?
InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.
How often is this page updated?
Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.